Responsible for advising clinical trial sponsors and consults with regulatory authorities and industry organizations to advance the knowledge of eClinical and patient reported outcomes. A member of the core committee for the DIA’s Study Endpoints SIAC and the DIA Annual Meeting Program Committee.
Ed Seguine is CEO of Clinical Ink, a provider of electronic source document technology. Previously he was CEO of Fast Track, General Manager of Medidata's Trial Planning products, and helped establish Eli Lilly's venture capital group. He has an MBA from Indiana University and a BS from BYU.
Dan Miller has been a clinical data manager for the last 12 years, working in CROs, EDC, pharma and biotech. Dan earned his certification from SCDM in 2007 and has trained and presented to a wide array of audiences in a variety of settings. Dan is a firm believer in cross functional collaboration.
John Humphreys is CTMS Product Director for Perceptive Informatics. A biochemist, John has worked with the pharmaceutical industry, and with pharmaceutical software, for the last 30 years. At Perceptive, he is responsible for the strategic direction of CTMS in an overall eClinical framework.
Description
Efficient fiscal management of clinical trials has always been important, but in today's environment of decreased R&D spending, the pressures for effective fiscal management of a drug or device trial have risen to an all time high. This session brings together a biopharmaceutical company representative and an eClinical vendor expert to discuss the economics and fiscal management of today's clinical trials.
Learning Objectives: Identify industry developments with respect to economics of today's clinical trials Describe new tools and processes for maximizing the limited fiscal resources of today's clinical trials.